TCR2 Therapeutics Reports Positive Interim Results From Ongoing Phase 1 Portion Of Gavo-cel Trial

(RTTNews) - TCR2 Therapeutics Inc. (TCRR) announced positive interim results from the ongoing phase 1 portion of the gavo-cel phase 1/2 clinical trial for mesothelin-expressing solid tumors. The company is very encouraged by the progression free survival and overall survival observed among patients with refractory mesothelioma treated so far with gavo-cel in the phase 1 trial. Gavo-cel was generally well tolerated with a manageable adverse event profile in the study.

The primary objectives of the phase 1 portion of the trial are to define the safety profile of gavo-cel in patients whose tumors overexpress mesothelin and to determine the recommended phase 2 dose. The company said the recommended phase 2 dose is being refined after identification of the maximum tolerated dose.

Alfonso Quintás-Cardama, Chief Medical Officer of TCR2, said: "Based on these data and the most recent patient experiencing a very mild safety profile at a cell dose of 3x108/m2, we believe the identification of the recommended phase 2 dose is close at hand."

Shares of TCR2 Therapeutics were up 4% in pre-market trade on Friday.